Bringing new cancer treatments to European patients: The challenge of making it across all three access milestones (Guest blog)
As part of EFPIA’s Time to Patient Initiative, we identified how European countries face delays in giving patients access to new cancer treatments. But overall, how big are the challenges of bringing new cancer treatments to European patients across all three access milestones of marketing authorization, market access and patient access? In this article, we’ll provide an overview. We identified ten reasons that explain most delays in giving European patients access to new cancer treatments. Here, our research focused on delays in ensuring market access and patient access. However, there is another access milestone preceding those two: marketing authorization. Let’s take a look at the overall picture of bringing new cancer treatments to European patients across all three access milestones.
Read the full blog here.
